In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
↖previous  1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  next↗
Company Name Title of Study Update Date
Eli Lilly and Company (Taiwan) A 2-year, Taiwan local observational study, of health outcomes and tolerability associated with atypical antipsychotics in outpatients of schizophrenia. 2006-04-13
Eli Lilly and Company (Taiwan) A 12-Month Prospective, Observational Study of Treatment Regimen and Quality of Life Associated with Attention Deficit Hyperactivity Disorder (ADHD) 2006-04-13
Servier Taiwan A monocenter, randomized, double-blind, add-on study of efficacy and safety of a very-low-dose combination of perindopril and indapamide - Preterax compared with cilazapril in the treatment of mild to moderate hypertensive patients 2006-02-15
Servier Taiwan A monocenter, double-blind, randomized, add-on study of efficacy and safety of a very- low-dose combination of perindopril and indapamide – Preterax compared with losartan in the treatment of mild to moderate treated hypertensive patients 2006-02-15
Bristol-Myers Squibb Taiwan Atazanavir for HIV infected individuals: Special access scheme Taiwan 2006-02-15
↙previous  1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  next↘

←HOME | ↑TOP